VASR BIOG : Letter from the CEO...

Nov 9, 2023

Dear Notable Community,

With the merger of Notable Labs and VBL Therapeutics completedand with NTBL publiclytrading on NASDAQ, I would like toofficiallywelcome and thank YOU- the newly combined group of shareholders, partners, employees, interested onlookers and allstakeholders - for your supportinachieving these milestones.I am excitedabout the prospect of jointly advancing our patient-focused mission.

With cancer having touched my own family, my journey to Notable carries with it a very personal understanding of the disease and appreciation of Notable's PPMP, ourproprietary Predictive Precision Medicines Platform,and its ability to predict, beforetreatment, whether a patient will clinically respond to their treatment (or not).

Predicting a patient's clinical response can matchtreatments with the patients who willmost likely respond, ensuring medical benefit for them and protecting the otherpatients, who traditionally would have been treated but not responded, from losing time,experiencingtoxicity, and wasting resources. At Notable, we believe each and everypatient deserves a treatment that will work for them.

Beyond improvingpatient outcomes, predictingtreatment response advances the development of novel medicines. Selectively enrolling predicted respondersinto clinical trialscanmaketrials more likely to succeedand besmaller, faster, and less costly. Bringing bettermedicines to patients fasterand more predictablybenefits all concerned.

Fueled by the integrated resources of two companies, our team is laser-focused on delivering severalclinical milestones of the Volasertib and Fosciclopiroxprograms between nowand 1Q 2025, expandingourrecent strong results of four clinical validation studies in partnership withStanford University, MD Anderson Cancer Center, and other recognized institutions.

I would also like to enthusiasticallywelcome our newBoard Directorsto Notable - industry leaders who havefounded, led, financed, and sold some of the most revolutionary and successful biopharmaceutical and life science companies. Their passion, diverse expertise,and commitment toour mission and visionwill be a tremendous asset to maximizingNotable's impact for patients and stakeholders.

Please do not hesitate to reach out- we always welcome your input as well as opportunities to collaborate.I look forward to a continuous dialogue with you as we launch a new era of PredictivePrecision Medicine together.

Thank you,

Thomas Bock